Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis

• Nishida, Yu

• Hosomi, Shuhei

• Watanabe, Kenji

• Watanabe, Kimihiko

• Yukawa, Tomomi

• Otani, Koji

• Nagami, Yasuaki

• Tanaka, Fumio

• Taira, Koichi

• Kamata, Noriko

• Yamagami, Hirokazu

• Tanigawa, Tetsuya

• Watanabe, Toshio

• Fujiwara, Yasuhiro

抄録

Objectives: Infliximab is effective in patients with ulcerative colitis (UC); however, one-third of patients do not respond and require additional therapies such as other biologic agents. Therefore, the aim of this study was to analyze the association between pro-inflammatory molecules and clinical efficacy to elucidate possible mechanisms for the non-response to infliximab to aid in treatment selection. / Materials and methods: Patients with moderate-to-severe active UC receiving infliximab in our hospital between 2010 and 2016 for whom pre-treatment serum samples were available were retrospectively evaluated. We analyzed the association between serum interleukin (IL)-6, tumor necrosis factor-α (TNF-α), and soluble mucosal vascular addressin cell adhesion molecule-1 (sMAdCAM-1) and the clinical efficacy of infliximab. The primary endpoint was clinical response at the end of the induction period....

収録刊行物

• Scandinavian Journal of Gastroenterology

  Scandinavian Journal of Gastroenterology 53 (5), 579-585, 2017-11-24

  Taylor & Francis

キーワード

• Infliximab
• tumor necrosis factor
• ulcerative colitis
• interleukin-6
• sMAdCAM

詳細情報

• CRID: 1050001202450521472
• NII論文ID: 120006595783
• NII書誌ID: AA12927667
• ISSN: 15027708
• ISSN: 00365521
• DOI: 10.1080/00365521.2017.1403647
• Web Site: https://dlisv03.media.osaka-cu.ac.jp/il/meta_pub/G0000438repository_15027708-53-5-579
• Web Site: https://www.tandfonline.com/doi/pdf/10.1080/00365521.2017.1403647
• 本文言語コード: en
• 資料種別: journal article
• データソース種別:
  • IRDB
  • Crossref
  • CiNii Articles
  • KAKEN